Related Experiment Video
Updated: Jun 17, 2026
PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator
Published on: December 28, 2017
Influence of imatinib mesylate on radiosensitivity of astrocytoma cells
E Ranza1, A Bertolotti, A Facoetti
1Department of Nuclear and Theoretical Physics, University of Pavia, Via Bassi 6, 27100 Pavia, Italy. elena_ranza@libero.it
Abstract:
Imatinib mesylate (STI571), an inhibitor of alpha- and beta-platelet-derived growth factor receptors (PDGFR) and other tyrosine kinases, is a well established treatment for chronic myeloid leukaemia and gastrointestinal stromal tumours. Moreover, it is under investigation for the therapy of several other malignant tumours since protein kinases are frequently mutated or otherwise deregulated in human malignancies and they serve as a target for differentiating between tumour cells and normal tissues. The objective of this study was to determine whether gamma radiation could sensitize astrocytoma cell lines to the effects of imatinib in vitro. For this purpose, T98G and MOG-G-UVW astrocytoma cells were treated with imatinib alone or in combination with gamma radiation. The clonogenic survival assays performed with the combination of imatinib with radiation demonstrated that the drug had an additive antiproliferative effect in both cell lines considered. Imatinib confered greater radiosensitivity on the T98G tumour cells effecting a significant decrease in colony formation compared with radiation alone. These data provide a rationale to further investigate the combination of imatinib with radiation, keeping in mind that this may result in unexpected toxicities that are not observed with either treatment alone.
Insights
This study investigated if gamma radiation enhances imatinib effectiveness against astrocytoma. Combining imatinib with radiation showed an additive antiproliferative effect, with imatinib increasing tumor cell radiosensitivity.
Area of Science:
- Oncology
- Radiation Oncology
- Molecular Biology
Background:
- Imatinib mesylate (STI571) targets platelet-derived growth factor receptors (PDGFR) and tyrosine kinases, approved for chronic myeloid leukemia and GIST.
- Protein kinases are crucial in cancer development and serve as therapeutic targets.
- Astrocytoma treatment options are limited, necessitating novel therapeutic strategies.
Purpose of the Study:
- To evaluate the radiosensitizing potential of imatinib in astrocytoma cell lines in vitro.
- To determine if combining imatinib with gamma radiation improves anti-cancer effects compared to monotherapy.
Main Methods:
- T98G and MOG-G-UVW astrocytoma cell lines were used for in vitro experiments.
- Cells were treated with imatinib alone, gamma radiation alone, or a combination of both.
- Clonogenic survival assays were performed to assess cell proliferation and survival.
Main Results:
- The combination of imatinib and gamma radiation demonstrated an additive antiproliferative effect in both astrocytoma cell lines.
- Imatinib significantly enhanced the radiosensitivity of T98G astrocytoma cells, reducing colony formation compared to radiation alone.
- MOG-G-UVW cells also showed increased sensitivity to radiation in the presence of imatinib.
Conclusions:
- Imatinib exhibits radiosensitizing properties in astrocytoma cell lines.
- The combination of imatinib and gamma radiation warrants further investigation as a potential therapeutic strategy for astrocytoma.
- Potential toxicities of combined treatment should be carefully evaluated in future studies.
